Drug
Gsk4527363
Gsk4527363: highest development phase Phase 1, developed by GlaxoSmithKline. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- GlaxoSmithKline
Trials
| Drug | Phase | Indication |
|---|---|---|
| GSK4527363 NCT06576271 | Phase 1 | Systemic Lupus Erythematosus |
Latest
No recent events.
Follow Gsk4527363 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.